|
Published by: Global Markets Direct
Published: Sep. 25, 2012 - 48 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Perennial Allergic Rhinitis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Perennial Allergic Rhinitis
- Perennial Allergic Rhinitis Therapeutics under Development by Companies
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Pre-Clinical Stage Products
- Comparative Analysis
- Perennial Allergic Rhinitis Therapeutics – Products under Development by Companies
- Companies Involved in Perennial Allergic Rhinitis Therapeutics Development
- Shionogi & Co., Ltd.
- GlaxoSmithKline plc
- Nycomed International Management GmbH
- Sun Pharmaceutical Industries Limited
- GenMont Biotech Inc.
- VentiRx Pharmaceuticals, Inc.
- Adamis Pharmaceuticals Corporation
- Perennial Allergic Rhinitis – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- ciclesonide - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- VTX-1463 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- S-555739 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- fluticasone furoate - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Modified Allergen Extract - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- GMNL-32 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SUN-1334 H - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- SUN-1334 H - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- TBS-6 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- APC-3000 - Drug Profile
- Product Description
- Mechanism of Action
- R&D Progress
- Perennial Allergic Rhinitis Therapeutics – Drug Profile Updates
- Perennial Allergic Rhinitis Therapeutics - Dormant Products
- Perennial Allergic Rhinitis – Product Development Milestones
- Featured News & Press Releases
- Nov 05, 2011: Sunovion’s Investigational Ciclesonide Nasal Aerosol In HFA Propellant, Demonstrated Positive Results In Patients With Perennial Allergic Rhinitis
- May 14, 1998: Rhone-Poulenc Rorer submits New Drug Application for once-daily, Non-Sedating Antihistamine
- Oct 20, 1995: Approval Of Kestine(Ebastine) Received in Denmark; New Antihistamine Now Approved in three European Countries
- Sep 13, 1994: Rhone-Poulenc Rorer And Fisons Sign Agreements To Market Respiratory Products In Europe
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Perennial Allergic Rhinitis, H2 2012
- Products under Development for Perennial Allergic Rhinitis – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Shionogi & Co., Ltd., H2 2012
- GlaxoSmithKline plc, H2 2012
- Nycomed International Management GmbH, H2 2012
- Sun Pharmaceutical Industries Limited, H2 2012
- GenMont Biotech Inc., H2 2012
- VentiRx Pharmaceuticals, Inc., H2 2012
- Adamis Pharmaceuticals Corporation, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Perennial Allergic Rhinitis Therapeutics – Drug Profile Updates
- Perennial Allergic Rhinitis Therapeutics – Dormant Products
- List of Figures
- Number of Products under Development for Perennial Allergic Rhinitis, H2 2012
- Products under Development for Perennial Allergic Rhinitis – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractPerennial Allergic Rhinitis – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Perennial Allergic Rhinitis - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Perennial Allergic Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis. Perennial Allergic Rhinitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Perennial Allergic Rhinitis.
- A review of the Perennial Allergic Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Perennial Allergic Rhinitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Perennial Allergic Rhinitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Perennial Allergic Rhinitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports,
company profiles and country profiles from over 720 research firms. Our reports will
provide you with the critical business and competitive intelligence you need for strategic planning and marketing
research. Coverage includes the US, UK, Europe, Asia and global markets.
|
